Exelixis Q2 revenue rises to $628.7 million and profit grows, but 2026 revenue guidance is cut
Exelixis reported second quarter 2026 total revenues of $628.7 million, up from $568.3 million a year earlier, and GAAP diluted EPS of $0.82, up from $0.65. However, the company lowered its full-year 2026 total revenue guidance to $2.500 billion-$2.550 billion from $2.525 billion-$2.625 billion, and the guidance excludes any revenue from a potential launch of zanzalintinib, which the FDA is reviewing with a December 3, 2026 target action date.
Key points
- Q2 2026 total revenues were $628.7 million vs. $568.3 million in Q2 2025; net product revenues were $573.0 million vs. $520.0 million.
- GAAP diluted EPS was $0.82 vs. $0.65 a year earlier; non-GAAP diluted EPS was $0.91 vs. $0.75.
- 2026 total revenue guidance was cut to $2.500 billion-$2.550 billion from $2.525 billion-$2.625 billion; net product revenue guidance was cut to $2.300 billion-$2.350 billion from $2.325 billion-$2.425 billion.
- Exelixis repurchased $311.6 million of its stock in Q2 2026 and began buybacks under a new $750 million authorization approved in May 2026.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.